| Literature DB >> 25766628 |
Jun-Bo He1, Hai-Feng He2, Lu-Lu Zhao2, Li Zhang2, Ge-Yun You2, Ling-Ling Feng2, Jian Wan3, Hong-Wu He4.
Abstract
To identify new antifungal lead compound based on inhibitors of pyruvate dehydrogenase complex E1, a series of 5-iodo-1,4-disubstituted-1,2,3-triazole derivatives 3 were prepared and evaluated for their Escherichia coli PDHc-E1 inhibitory activity and antifungal activity. The in vitro bioassay for the PDHc-E1 inhibition indicated all the compounds exhibited significant inhibition against E. coli PDHc-E1 (IC50<21μM), special compound 3g showed the most potent inhibitory activity (IC50=4.21±0.11μM) and was demonstrated to act as a competitive inhibitor of PDHc-E1. Meanwhile, inhibitor 3g exhibited very good enzyme-selective inhibition of PDHc-E1 between pig heart and E. coli. The assay of antifungal activity showed compounds 3e, 3g, and 3n exhibited fair to good activity against Rhizoctonia solani and Botrytis cinerea even at 12.5μg/mL. Especially compound 3n (EC50=5.4μg/mL; EC90=21.1μg/mL) exhibited almost 5.50 times inhibitory potency against B. cinerea than that of pyrimethanil (EC50=29.6μg/mL; EC90=113.4μg/mL). Therefore, in this study, compound 3n was found to be a novel lead compound for further optimization to find more potent antifungal compounds as microbial PDHc-E1 inhibitors.Entities:
Keywords: 5-Iodo-1,4-disubstituted-1,2,3-triazole; Antifungal activity; Inhibitor; Pyruvate dehydrogenase complex
Mesh:
Substances:
Year: 2015 PMID: 25766628 DOI: 10.1016/j.bmc.2015.02.047
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641